The developing brain is an important target of thyroid hormones. A complex regulatory network involving transfer of thyroid hormones through the brain barriers, interactions between neurons and glial cells, and deiodinase expression, works to deliver the appropriate amount of T 3 to the nuclear receptors. The data provided by Heuer et al. (1) in this issue indicates that specific thyroid hormone transporters may also be an essential part of this regulatory system.
Thyroid hormones influence brain development from about the end of the first trimester of fetal life. The human fetal brain expresses nuclear T 3 receptors at least from the 10th week of gestation, and receptor concentration increases 10-fold during the second trimester in brain and other tissues (2) . T 4 is present in brain and other tissues, such as liver, kidney, and lung, but T 3 is detectable only in brain, at concentrations that result in an occupancy of brain T 3 receptors around 25%. The source of T 4 reaching the fetal brain up to midgestation is mostly of maternal origin (3). Both T 4 and T 3 cross the placenta and reach the fetal organs, but only T 4 appears to cross the fetal blood-brain barrier. Thus, the administration of T 3 by constant infusion to pregnant rat dams increased T 3 concentrations in all maternal and fetal tissues except the fetal brain (4) . In contrast, the administration of T 4 increased T 3 content in fetal brain as well as in other tissues. There was also a very important difference between the brain and the rest of the tissues. When increasing amounts of T 4 were administered to pregnant dams maintained on methimazole, normal concentrations of T 3 in the fetal brain were kept over a much wider range of T 4 doses than in other tissues.
In adult rats, both T 4 and T 3 reach the brain from blood, but it was estimated that as much as 80% of the T 3 bound to the nuclear receptors was produced locally by type 2 deiodinase (D2) activity (5) . As in fetal brain, when either T 4 or T 3 was administered to hypothyroid rats, the T 3 content of the brain was maintained within control values only by T 4 , but not by T 3 , infusion (6) . Homeostasis of T 3 within the brain is maintained within narrow limits by a complex mechanism involving D2 and D3. Several years ago we reported that D2 was predominantly expressed in glial cells of two types, tanycytes and astrocytes (7) (Fig. 1) . Tanycytes, in which expression of D2 was also reported by Tu et al. (8) , are specialized ependymal cells lining the third ventricle and extending processes to the adjacent hypothalamus and the median eminence. The T 3 generated by these cells from cerebrospinal T 4 could play a role in TRH-TSH regulation. On the other hand, expression of D2 in the astrocytes suggested to us the existence of interplay between astrocytes and neurons on T 3 homeostasis similar to the metabolic coupling between the two cells concerning the glutamate-glutamine cycle or glucose use (9) . Astrocytes would produce T 3 for neuronal use. As an additional control of neuronal T 3 concentration, D3, which degrades T 3 to the inactive metabolite diiodothyronine, is expressed in neurons. In this issue, Heuer et al. (1) confirm expression of D2 in the astrocytes and suggest important roles in T 3 homeostasis for recently characterized thyroid hormone transporters (Fig. 1) .
The entry of thyroid hormones into the cells has for a long time been assumed to be by passive diffusion, because thyroid hormones are lipophilic molecules and as such could easily enter the membrane lipid bilayer. Experiments in vivo hardly gave any hint of a saturable process, as was, for example, the binding of T 3 to the nucleus, an observation that facilitated the discovery of nuclear receptors. However, in isolated hepatocytes and other cell types, the demonstration of relatively high-affinity sites for both T 4 and T 3 , and the inhibition of cellular uptake by metabolic inhibitors, amino Abbreviations: D2, Type 2 deiodinase; MCT, monocarboxylate anion transporters; OATP, organic anion-transporting polypeptides.
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FIG. 1.
Thyroid hormones are transported through the blood-brain barrier (OATP) or the blood-CSF barrier (OATP and MCT8). In the astrocytes and tanycytes T 4 is converted to T 3 which then enters the neurons through MCT8. In the neurons both T 4 and T 3 are degraded by D3. T 3 from the tanycytes may reach the portal vessels in the median eminence. Other transporters may be present on the astrocyte or tanycyte membranes. In most cases the transport could be bidirectional, although only one direction is shown.
acids, and other chemicals, gave evidence for the physiological significance of thyroid hormone transporters (10) . Several molecular entities have been identified as transporters for thyroid hormone (11) . They belong to three main families: the organic anion-transporting polypeptides (OATP), the Lamino acid transporters, and the monocarboxylate anion transporters (MCT).
Among the many members of the OATP family, human OATP-F (12) and rat Oatp14 (13) are preferentially expressed in brain. The Oatp14 protein is localized in the border of brain capillary endothelial cells and in the choroid plexus. OATP-F/Oatp14 transports T 4 and rT 3 much more efficiently than T 3 , and might be involved in the transport of T 4 through the blood-brain barrier and through the choroid plexus, and also in rT 3 clearance. The blood-brain barrier is the route by which thyroid hormone is preferentially distributed throughout the brain, and this transporter could facilitate uptake of T 4 by the astrocytes. Transfer of thyroid hormone through the choroid plexus achieves only limited diffusion to the brain parenchyma after passage to the cerebrospinal fluid but would allow uptake of T 4 by tanycytes and subsequent T 3 generation in these cells.
The MCT family comprises up to 14 members, some of which are involved in the transport of important substrates for the brain such as lactate and pyruvate. MCT8 has been shown to act as a specific transporter for T 4 and T 3 and displays slightly higher affinity for T 3 (14) . Heuer et al. (1) have also studied the regional expression of MCT8 mRNA. In addition to high expression levels in the choroid plexus, they found that MCT8 is expressed in neurons of the neocortex, hippocampus, basal ganglia, amygdala, hypothalamus, and the Purkinje cells of the cerebellum, all regions known to be sensitive to thyroid hormones (15) . Expression of MCT8 in neurons suggests that neuronal uptake of the T 3 produced in astrocytes is facilitated by this transporter.
The physiological significance of MCT8 as a transporter for thyroid hormone is supported by the finding of mutations in humans by Dumitrescu et al. (16) and Friesema et al. (17) . The syndrome affects children from an early age and consists of severe developmental delay and neurological damage together with an unusually altered pattern of thyroid hormone levels in blood. The patients presented low total and free T 4 , high total and free T 3 , and low rT 3 . TSH was moderately elevated in two of the patients and normal or slightly elevated in the other five. Inactivating mutations of the MCT8 transporter could result in the altered thyroid hormone levels. In vitro uptake of T 4 and T 3 by fibroblasts isolated from affected males was strongly reduced, and intracellular D2 was increased 6-to 8-fold (17) . It is thus hypothesized that the resulting increase in intracellularly generated T 3 accumulates in blood because of its poor reuptake into cells. In addition, deficient uptake of T 4 and T 3 by neurons could reduce degradation by neuronal D3 to rT 3 and diiodothyronine, respectively, with increased T 3 and decreased rT 3 . The brain and skin are predominant sites of D3 expression, but their contribution to T 3 degradation and to blood rT 3 is difficult to estimate (18) .
The neurological syndrome caused by MCT8 mutations consists of developmental delays, rotary nystagmus, severe proximal hypotonia with poor head control, spastic quadriplegia, dystonic movements, and impaired gaze and hearing. More recently, a syndrome of paroxysmal dyskinesia has been recognized by Brockmann et al. (19) in the two patients originally described by Dumitrescu et al. (16) . The whole clinical picture is so severe that it is pertinent to ask the question of whether the impaired uptake and action of thyroid hormone on neurons could cause such a syndrome. The neurological disorder of endemic cretinism (neurological cretinism) consists of variable degrees of neuromotor affectation with proximal limb girdle spasticity and rigidity, more often affecting the lower extremities, extrapyramidal disorders of rigidity and bradykinesia, deaf-mutism, strabismus, dysarthria, and mental deficiency (20) . Epidemiological and physiopathological considerations indicate that this syndrome is most probably a result of lack of thyroid hormone during fetal development, especially before midgestation. This is the period of neuroblast proliferation and maturation of the basal ganglia and cerebral cortex. In the postmortem examination of the maternal uncle of one of the patients, also probably affected, loss of neurons in the cerebral cortex, basal ganglia, and cerebellum was found (16). As mentioned above, the second trimester is also the period when thyroid hormone receptors increase in concentration in the brain. If MCT8 is needed at this stage of development for T 3 entry into neurons, mutations of the transporter could also interfere with T 3 -dependent developmental processes. Knowledge of the ontogenetic patterns of MCT8 in the human fetal brain would certainly be helpful. On the other hand, there is also the possibility that MCT8 mutations interfere with transport of other substrates for brain metabolism that could be even more important than T 3 in determining the severity and outcome of the syndrome. Other members of the family transport metabolic substrates such as pyruvate and lactate, but MCT8 so far appears to be specific for iodothyronines (14) .
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